Research Progress of Radiolabeled Asn-Gly-Arg (NGR) Peptides for Imaging and Therapy
- PMID: 32862776
- PMCID: PMC7466889
- DOI: 10.1177/1536012120934957
Research Progress of Radiolabeled Asn-Gly-Arg (NGR) Peptides for Imaging and Therapy
Abstract
Asn-Gly-Arg (NGR) motifs have vasculature-homing properties via interactions with the aminopeptidase N (CD13) expressed on tumor neovasculature. Numerous NGR peptides with different molecular scaffolds have been exploited for targeted delivery of different compounds for imaging and therapy. When conjugated with NGR, complexes recognize the CD13 receptor expressed on the tumor vasculature, which improves the specificity to tumor and avoids systematic toxic reactions. Both preclinical and clinical studies performed with these products suggest that NGR-mediated vascular targeting is an effective strategy for delivering bioactive amounts of cytokines to tumor endothelial cells. For molecular imaging, radiolabeled peptides have been the most successful approach and have been translated into clinic. This review describes current data on radiolabeled tumor vasculature-homing NGR peptides for imaging and therapy.
Keywords: NGR; imaging; radiolabeled; therapy; tumor.
Conflict of interest statement
Figures
References
-
- Angelo C, Curnis F. Tumor vasculature targeting through NGR peptide-based drug delivery systems. Curr Pharm Biotechnol. 2011;12(8):1128–1134. - PubMed
-
- Flavio C, Anna G, Angelina S, Cattaneo A, Magni F, Corti A. Targeted delivery of IFN; to tumor vessels uncouples antitumor from counterregulatory mechanisms. Cancer Res. 2005;65(7):2906–2913. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
